Page 2 - Randomized Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Theriva Biologics, Inc : Theriva Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Theriva Biologics, Inc : Theriva Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesDennis riedlTheriva biologicsChris calabreseAmerican society of clinical oncologyLifesci advisorsTheriva biologics incClinical oncologyAnnual meetingRandomized studyMetastatic pancreaticPoster sessionSession dateSci advisorsAktien sie

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHolli kolkeyZeva wainbergTerry rosenYelenay janjigianMemorial sloan kettering cancer centerAmerican society of clinical oncologyArcus biosciences incGilead sciencesGastrointestinal oncology programCorporate communicationsChief gastrointestinal oncologyLead investigatorOncology programClinical oncologyAnnual meeting

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal cancers will be presented in a special ASCO plenary series rapid abstract update.

United statesTerry rosenGilead sciencesArcus biosciences incAmerican society of clinical oncologyArcus biosciencesClinical oncologyAnnual meetingRapid abstract updatesLung cancerNon small cellRandomized studyPreviously treated metastatic colorectal cancerOral abstract sessionArcus bioscience

Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency

/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.

United statesBiomedical advanced researchExchange commissionUs congressPrnewswire soligenix incEuropean medicines agencyDefense threat reduction agencyDevelopment authoritySoligenix incOur public health solutionsNational institute of allergyRandomized studyContinuous treatment expectedExtend resultsStatistically significant phaseAbout hybryte

FDA Grants BLA for Dato-DXd to Treat Unresectable, Metastatic HR-Positive, HER2-Negative Breast Cancer

The decision follows phase 3 trial results that demonstrated improved progression-free survival and confirmed the safety of Dato-DXd in patients with breast cancer.

Ken takeshitaSusan galbraithDaiichi sankyoSebastian kaulitzkiRandomized studyVersus investigatorParticipants with inoperableTwo prior lines